MedTrace Logo

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

NCT01094769 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-09-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether moxonidine is effective in reducing urine albumin levels in patients with diabetic kidney disease.

Conditions

  • Diabetic Nephropathies

Interventions

DRUG

Moxonidine

Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.

DRUG

Placebo

lactose capsule taken once daily

Sponsors & Collaborators

  • Baker Heart and Diabetes Institute

    lead OTHER

Principal Investigators

  • Markus P Schlaich, MD · Baker Heart and Diabetes Institute

  • Gavin W Lambert, BSc PhD · Baker Heart and Diabetes Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2020-01-31
Completion
2020-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01094769 on ClinicalTrials.gov